Maya Beganovic1,2, Jaclyn A Cusumano1,2, Vrishali Lopes1, Kerry L LaPlante1,2,3,4, Aisling R Caffrey1,2,3,5. 1. Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Rhode Island. 2. College of Pharmacy, University of Rhode Island, Kingston. 3. Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center, Rhode Island. 4. Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, Rhode Island. 5. Brown University School of Public Health, Providence, Rhode Island.
Abstract
OBJECTIVE: Beta-lactam antibiotics are recommended as first-line for treatment of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia. The objective of this study was to compare effectiveness of anti-MSSA therapies among bacteremia patients exclusively exposed to 1 antimicrobial. METHOD: This was a national retrospective cohort study of patients hospitalized in Veterans Affairs medical centers with MSSA bacteremia from January 1, 2002, to October 1, 2015. Patients were included if they were treated exclusively with nafcillin, oxacillin, cefazolin, piperacillin/tazobactam, or fluoroquinolones (moxifloxacin and levofloxacin). We assessed 30-day mortality, time to discharge, inpatient mortality, 30-day readmission, and 30-day S. aureus reinfection. Hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using propensity-score (PS) matched Cox proportional hazards regression model. RESULTS: When comparing nafcillin/oxacillin (n = 105) with cefazolin (n = 107), 30-day mortality was similar between groups (PS matched n = 44; HR, 0.67; 95% CI, 0.11-4.00), as were rates of the other outcomes assessed. As clinical outcomes did not vary between nafcillin/oxacillin and cefazolin, they were combined for comparison with piperacillin/tazobactam (n = 113) and fluoroquinolones (n = 103). Mortality in the 30 days after culture was significantly lower in the nafcillin/oxacillin/cefazolin group compared with piperacillin/tazobactam (PS matched n = 48; HR, 0.10; 95% CI, 0.01-0.78), and similar when compared with fluoroquinolones (PS matched n = 32; HR, 1.33; 95% CI, 0.30-5.96). CONCLUSIONS: In hospitalized patients with MSSA bacteremia, no difference in mortality was observed between nafcillin/oxacillin and cefazolin or fluoroquinolones. However, higher mortality was observed with piperacillin/tazobactam as compared with nafcillin/oxacillin/cefazolin, suggesting it may not be as effective as a monotherapy in MSSA bacteremia.
OBJECTIVE: Beta-lactam antibiotics are recommended as first-line for treatment of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia. The objective of this study was to compare effectiveness of anti-MSSA therapies among bacteremia patients exclusively exposed to 1 antimicrobial. METHOD: This was a national retrospective cohort study of patients hospitalized in Veterans Affairs medical centers with MSSA bacteremia from January 1, 2002, to October 1, 2015. Patients were included if they were treated exclusively with nafcillin, oxacillin, cefazolin, piperacillin/tazobactam, or fluoroquinolones (moxifloxacin and levofloxacin). We assessed 30-day mortality, time to discharge, inpatient mortality, 30-day readmission, and 30-day S. aureus reinfection. Hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using propensity-score (PS) matched Cox proportional hazards regression model. RESULTS: When comparing nafcillin/oxacillin (n = 105) with cefazolin (n = 107), 30-day mortality was similar between groups (PS matched n = 44; HR, 0.67; 95% CI, 0.11-4.00), as were rates of the other outcomes assessed. As clinical outcomes did not vary between nafcillin/oxacillin and cefazolin, they were combined for comparison with piperacillin/tazobactam (n = 113) and fluoroquinolones (n = 103). Mortality in the 30 days after culture was significantly lower in the nafcillin/oxacillin/cefazolin group compared with piperacillin/tazobactam (PS matched n = 48; HR, 0.10; 95% CI, 0.01-0.78), and similar when compared with fluoroquinolones (PS matched n = 32; HR, 1.33; 95% CI, 0.30-5.96). CONCLUSIONS: In hospitalized patients with MSSA bacteremia, no difference in mortality was observed between nafcillin/oxacillin and cefazolin or fluoroquinolones. However, higher mortality was observed with piperacillin/tazobactam as compared with nafcillin/oxacillin/cefazolin, suggesting it may not be as effective as a monotherapy in MSSA bacteremia.
Authors: M Paul; N Zemer-Wassercug; O Talker; Y Lishtzinsky; B Lev; Z Samra; L Leibovici; J Bishara Journal: Clin Microbiol Infect Date: 2010-12-14 Impact factor: 8.067
Authors: Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove Journal: N Engl J Med Date: 2006-08-17 Impact factor: 91.245
Authors: E Ruotsalainen; A Järvinen; I Koivula; H Kauma; E Rintala; J Lumio; P Kotilainen; M Vaara; J Nikoskelainen; V Valtonen Journal: J Intern Med Date: 2006-02 Impact factor: 8.989
Authors: Jacques Schrenzel; Stephan Harbarth; Gérard Schockmel; Daniel Genné; Thomas Bregenzer; Ursula Flueckiger; Christiane Petignat; Frédérique Jacobs; Patrick Francioli; Werner Zimmerli; Daniel P Lew Journal: Clin Infect Dis Date: 2004-10-11 Impact factor: 9.079
Authors: Esteban C Nannini; Martin E Stryjewski; Kavindra V Singh; Agathe Bourgogne; Tom H Rude; G Ralph Corey; Vance G Fowler; Barbara E Murray Journal: Antimicrob Agents Chemother Date: 2009-06-01 Impact factor: 5.191
Authors: Robert Strengen Bigseth; Håkon Sandholdt; Andreas Petersen; Christian Østergaard; Thomas Benfield; Louise Thorlacius-Ussing Journal: Microbiol Spectr Date: 2022-04-19
Authors: Jaclyn A Cusumano; Amy C Dupper; Yesha Malik; Elizabeth M Gavioli; Jaspreet Banga; Ana Berbel Caban; Devika Nadkarni; Ajay Obla; Chirag V Vasa; Dana Mazo; Deena R Altman Journal: Open Forum Infect Dis Date: 2020-11-12 Impact factor: 3.835
Authors: Daniele Roberto Giacobbe; Silvia Dettori; Silvia Corcione; Antonio Vena; Chiara Sepulcri; Alberto Enrico Maraolo; Francesco Giuseppe De Rosa; Matteo Bassetti Journal: Infect Drug Resist Date: 2022-04-22 Impact factor: 4.177
Authors: Muneerah M Aleissa; Isabel H Gonzalez-Bocco; Sara Zekery-Saad; David W Kubiak; Eric M Zhang; Jessie Signorelli; Sarah P Hammond; Amir M Mohareb; Marlise R Luskin; Jennifer Manne-Goehler; Francisco M Marty Journal: Open Forum Infect Dis Date: 2022-06-20 Impact factor: 4.423